The bladder tumour was tested with the Dako PD-L1 IHC 22C3 pharmDx test (Agilent Technologies, Santa Clara, CA, USA) to assess suitability for pembrolizumab therapy and Ventana PD-L1 SP142 assay (Ventana Medical Systems, Inc., Tucson, AZ, USA) to determine suitability for atezolizumab therapy, for which both tested negative for PD-L1 expression; hence, she is not eligible for immunotherapy. The gene discussed is CD274; the disease is urinary bladder neoplasm.